Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses the phase III findings from the Alliance A031201 trial, which showed that adding abiraterone acetate to enzalutamide did not improve survival in men with metastatic castration-resistant prostate cancer (Abstract 5008).
Amy J. Davidoff, PhD, of Yale University School of Public Health, discusses study findings on how expanding access to Medicaid through the Affordable Care Act (ACA) reduced r...
Don S. Dizon, MD, of the Lifespan Cancer Institute, and Mansoor Raza Mirza, MD, of Copenhagen University Hospital, discuss study findings that showed, compar...
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Ian D. Davis, MBBS, PhD, of Monash University and Eastern Health, discuss the Australian and ...
Justin F. Gainor, MD, of Massachusetts General Hospital, discusses updated findings from the ARROW study in which BLU-667, a selective RET inhibitor, demonstrated clinical ac...
Josep Tabernero, MD, PhD, of the Vall d’Hebron Institute of Oncology, discusses phase III findings of the KEYNOTE-062 study showing that, for some patients with advanced gast...
